Yasuo Terauchi
Overview
Explore the profile of Yasuo Terauchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
378
Citations
8210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaneto H, Hatanaka M, Morimoto Y, Takahashi Y, Terauchi Y
Adv Ther
. 2025 Mar;
PMID: 40056372
Introduction: In this post-marketing study in Japan, the occurrence of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment was evaluated in various cohorts of people with type 2 diabetes (T2D)...
2.
Okuyama T, Tsuno T, Inoue R, Fukushima S, Kyohara M, Matsumura A, et al.
iScience
. 2025 Feb;
28(2):111856.
PMID: 39995864
The matricellular protein Fibulin-5 (Fbln5) is a secreted protein that is essential for elastic fiber formation, and pancreatic islets are usually surrounded by the extracellular matrix (ECM), which includes elastic...
3.
Shigesawa I, Nakamura A, Yamauchi Y, Kawata S, Miyazaki A, Nomoto H, et al.
J Diabetes Investig
. 2024 Sep;
15(12):1732-1742.
PMID: 39305123
Aims/introduction: We previously showed that glucokinase haploinsufficiency improves the glucose tolerance of db/db mice by preserving pancreatic β-cell mass and function. In the present study, we aimed to determine the...
4.
Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, et al.
J Diabetes Investig
. 2024 Aug;
15(11):1566-1577.
PMID: 39172634
Aims/introduction: PIONEER REAL Japan was a non-interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Materials And Methods: Adults naïve to injectable glucose-lowering...
5.
Yamada Y, Yabe D, Shide K, Suzuki A, Terauchi Y, Sato Y, et al.
J Diabetes Investig
. 2024 Aug;
15(11):1585-1595.
PMID: 39141404
Aims/introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety....
6.
Kondo Y, Satoh S, Terauchi Y
Diabetol Int
. 2024 Aug;
15(3):474-482.
PMID: 39101164
Aims: This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes. Materials And Methods: For 24 weeks, participants...
7.
Waki K, Nara M, Enomoto S, Mieno M, Kanda E, Sankoda A, et al.
NPJ Digit Med
. 2024 Jun;
7(1):155.
PMID: 38879663
No abstract available.
8.
Suzuki T, Orime K, Akamatsu R, Akiyama T, Yamakawa T, Terauchi Y
Intern Med
. 2024 May;
63(24):3339-3344.
PMID: 38719597
Patients often present with severe fatty liver (FL) due to insulin deficiency at the onset of diabetic ketoacidosis (DKA). On the other hand, glycogenic hepatopathy (GH) is a possible cause...
9.
Waki K, Nara M, Enomoto S, Mieno M, Kanda E, Sankoda A, et al.
NPJ Digit Med
. 2024 Apr;
7(1):104.
PMID: 38678094
We evaluated the effectiveness of a mobile health (mHealth) intervention for diabetic kidney disease patients by conducting a 12-month randomized controlled trial among 126 type 2 diabetes mellitus patients with...
10.
Terui S, Igari M, Tsuno T, Okuyama T, Inoue R, Kyohara M, et al.
Diabetes Ther
. 2024 Mar;
15(5):1139-1153.
PMID: 38494572
Introduction: As treatment agents for diabetes, liraglutide is a long-acting glucagon-like peptide 1 receptor agonist, and dipeptidyl peptidase 4 (DPP4) inhibitors are widely used because of their safety and tolerability....